Gene-modified cellular vaccines: Technologic aspects and clinical problems

Transplantation Proceedings

Volumn 42, Issue 8, 2010, Pages 3287-3292

  MacKiewicz, J ^a   MacKiewicz, A ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AGI 101H; BIOLOGICAL MARKER; CANCER VACCINE; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; MELACINE; PROVENGE; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL COUNT; CELL VIABILITY; COLON CANCER; CYTOTOXICITY; DNA MODIFICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG IMPURITY; DRUG INDICATION; DRUG MANUFACTURE; DRUG POTENCY; DRUG PURITY; HUMAN; MELANOMA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY CONTROL; STANDARDIZATION; TREATMENT OUTCOME;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; QUALITY CONTROL;

EID: 77958570368     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.07.028     Document Type: Article

References (31)

1. S. Pejwar-Gaddy, and O.J. Finn Cancer vaccines: accomplishments and challenges Crit Rev Oncol Hematol 67 2008 93
2. J. Mackiewicz, and A. Mackiewicz Design of clinical trial for therapeutic cancer vaccine development Eur J Pharmacol 625 2009 84
3. U. Vaishampayan, J. Abrams, and D. Darrah Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha Clin Cancer Res 8 2002 3696
4. M.S. Mitchell, W. Harel, and S. Groshen Association of HLA phenotype with response to active specific immunotherapy of melanoma J Clin Oncol 10 1992 1158
5. J.A. Sosman, J.M. Unger, and P.Y. Liu Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome J Clin Oncol 20 2002 2067
6. V. Sondak, J. Sosman, and J.M. Unger Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine Final analysis of SWOG-9035 J Clin Oncol 22 2004 7501
7. C.A. Uylde Groot, J.B. Vermorken, and M.G. Hanna Jr Immunotherapy with autologous tumor cellBCG vaccine in patients with colon cancer: a prospective study of medicinal and economic benefits Vaccine 23 2005 2379
8. Bringing therapeutic cancer vaccines and immunotherapies through development to licensure, February 89, 2007 https://cms.palladianpartners.com/ cms/1156354418/home.htm Videocast available at: http://videocast.nih.gov/
9. http://www.clinicaltrial.gov/ct2/show/NCT00089856
10. http://www.clinicaltrial.gov/ct2/show/NCT00133224
11. Schellhammer PF, Higano C, Berger ER,, et al. A randomized, double-blind, placebo-controlled, multi-center, phase III trial of Sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC). Presented at the American Urological Association 104th Annual Scientific Meeting ( 9)
12. Committee for Human Medicinal Products, European Medicinal Agency Draft guideline on human cell-based medicinal products: EMEA/CHMP/410869/2006 http://www.emea.europa.eu/pdfs/cpwp/410869en.pdf
13. International Conference on Harmonization: Guideline Q6B, specifications: test procedures and acceptance criteria for biotechnological/biological products, March 10, 1999
14. WHO Expert Committee on Biological Standardization WHO technical report series: guidelines for the production and quality control of synthetic peptide vaccines Annex 1 Technical Report Series 889 1999 38
15. J. Petricciani, W. Egan, and G. Vicari Potency assays for therapeutic live whole cell cancer vaccines Biologicals 35 2007 107
16. Committee For Medicinal Products for Human Use, European Medicines Agency Guideline for potency testing of cell-based immunotherapy medicinal products for treatment of cancer: EMEA/CHMP/410869/2006 http://www.emea.europa.eu/pdfs/ human/bwp/27147506en.pdf
17. S. Ward, J. Copier, and A. Dalgleish Technical challenges facing therapeutic cancer vaccines Curr Opin Drug Discov Devel 11 2008 168
18. EMEA/CHMP: Note for guidance on the quality, preclinical and clinical aspects of gene transfer medicinal products (CPMP/BWP/3008/99)
19. L.H. Finke, and K. Wentworth Lessons from randomized phase III studies with active cancer immunotherapiesoutcomes from the 2006 Meeting of the Cancer Vaccine Consortium (CVC) Blumenstein Vaccine 25S 2007 B97
20. J. Copier, S. Ward, and A. Dalgleish Cell based cancer vaccines: regulatory and commercial development Vaccine 25S 2007 B35
21. L.C. Michaelis, and M. Ratain Measuring response in a post-RECIST world: from black and white to shades of grey Nat Rev Cancer 6 2006 409
22. S. Nawrocki, and A. Mackiewicz Clinical trials of active cancer immunotherapy Expert Opin Investig Drugs 16 2007 1137
23. R.M. Simon, S.M. Steinberg, and M. Hamilton Clinical trial designs for the early clinical development of therapeutic cancer vaccines J Clin Oncol 19 2001 1848
24. J. Stebbing, C. Wood, and M. Atkins Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments Cancer 112 2008 955
25. J. Copier, A. Dalgleish, and C.M. Britten Improving the efficacy of cancer immunotherapy Eur J Cancer 45 2009 1424
26. A. Hoos, G. Parmiani, and K. Hege A clinical development paradigm for cancer vaccines and related biologics J Immunother 30 2007 1
27. S. Nawrocki, P. Murawa, and J. Malicki Genetically modified tumour vaccines (GMTV) in melanoma clinical trials Immunol Lett 15 2000 81
28. J.D. Wolchok, A. Hoos, and S. O'Day Guidelines for evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 2009 7412
29. S. Gutman The Food and Drug Administration perspective on cancer biomarker development Kessler Nat Rev Cancer 6 2006 565
30. J. Copier, and A. Dalgleish Improving the efficacy of cancer immunotherapy Britten Eur J Cancer 45 2009 1424
31. L.J. Sannes Immunotherapies and vaccines for cancer and infectious diseases Insight Pharma Reports. Cambridge Health Institute, 2008 http://www.insightpharmareports.com